ACLA News

The American Clinical Laboratory Association Announces the Promotion of Julie Khani to Executive Vice President

(Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today announced the promotion of Julie Khani to Executive Vice President (EVP) by the ACLA Board of Directors for the nation’s leading organization representing clinical laboratories. Khani joined ACLA in the newly created position of Senior Vice President in 2013 to oversee the advocacy and policy operations and ACLA’s divisional vice presidents. In her new role as EVP, Khani will take on additional management responsibilities encompassing association operations and policy initiatives impacting the clinical laboratory industry.

“Julie’s tenure at ACLA has been marked by outstanding leadership and a keen understanding of public policy that has helped position ACLA before Congress and the administration as a leading advocate and expert on clinical laboratory issues,” said Alan Mertz, President of ACLA. “Clinical laboratories are faced with numerous challenges involving reimbursement and regulatory oversight and Julie’s command of the issues and her strategic direction are enormous assets for ACLA.”

Prior to joining ACLA, Khani served in senior roles at the National Association of Chain Drug Stores (NACDS) as Vice President, Public Policy, and formerly Director, Federal Legislative Affairs. During her tenure at NACDS, Khani was instrumental in the inclusion of pharmacy access standards in the Medicare Part D benefit, establishing incentives for TRICARE beneficiaries to obtain immunizations at retail pharmacies, and played a leading role in implementation of the Affordable Care Act provisions on pharmacy reimbursement for generic drugs. Previously, Khani served as Legislative Manager at Ford Motor Company, where she was responsible for health and labor issues and the company’s political action committee. She holds a bachelor of arts from New York University and a master of public administration from George Washington University.

“Diagnostic innovation has hit center stage as personalized medicine and its life-changing ramifications have become a reality in efforts to prevent and treat cancer and other diseases,” said Khani. “This is an exciting time to be a part of an industry that is making a difference in the lives of patients and I look forward to advancing the goals and mission of the clinical laboratory community.”

 

# # #
The ACLA is a not-for-profit association representing the nation’s leading national, regional and esoteric clinical laboratories on key issues of common concern, including federal and state government reimbursement and regulatory policies.

Print Friendly, PDF & Email